Data Analytics Could Enable Trial Diversity And Meet New Regulations

By Rohit Nambisan, Lokavant

Efforts to enhance diversity, equity, and inclusion (DEI) access within the U.S. healthcare system have emerged as a crucial and overdue development in recent years. In December 2022, comprehensive DEI legislation was enacted in the nation, effective from February 2023, aiming to address significant disparities and placing the responsibility on sponsors to ensure diverse representation in clinical trials.

The importance of diverse participant populations in clinical trials was further emphasized during the pandemic's vaccine development, as it became paramount to understand the real-world implications of novel therapies on safety and efficacy.

While clinical trial participation among minority groups in the U.S. has remained woefully inadequate, researchers believe that data analytics tools can play a valuable role in improving participation. Explore the ways that data analytics could serve as a reliable mechanism to ensure the representation of diverse participants in their trials and meet new regulations.